Deciphera says its drug for rare joint tumor succeeded in a PhIII study, will submit to FDA
Deciphera Pharmaceuticals’ experimental treatment for tenosynovial giant cell tumor passed a pivotal study, setting the biotech up to go for its second drug approval. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
